Novel Vaccine Adjuvants

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 117

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medicine, UC San Diego, La Jolla, CA 92037, USA
Interests: vaccines; adjuvants; immunology

E-Mail Website
Guest Editor
Moores Cancer Center, San Diego, CA, USA
Interests: vaccines; adjuvants; virus; immunology; antibodies; T cells

Special Issue Information

Dear Colleagues,

Adjuvants are an important component for making effective vaccines. While aluminum salts (alum) were approved as a vaccine adjuvant many years ago, only a few adjuvants have been approved for human use in recent years, including MPLA, CpG1018, and MF59. There is a lot of ongoing research regarding the identification of novel vaccine adjuvants such as Toll-like receptor agonists, RIG-I-like receptor agonists, NOD-like receptor agonists, adjuvants for adjuvant or co-adjuvants, exosome-inducing adjuvants, select polysaccharides, etc. Thus, the aim of this Special Issue is to present readers with articles that focus on the discovery and development of such novel vaccine adjuvants, their synthesis and production, their efficacy in disease models, their mechanisms of actions, and other studies comparing adjuvants.

Dr. Fumi Sato-Kaneko
Dr. Nikunj M. Shukla
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine
  • adjuvants
  • TLRs
  • innate immunity
  • adaptive immunity
  • exosome
  • influenza
  • COVID
  • virus

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop